Evolus: US FDA validates troubled CMO site, but rejects BOTOX alternative

By Flora Southey contact

- Last updated on GMT

Evolus says its South Korean CMO has successfully addressed GMP violations, but US FDA is yet to approve the firm’s alternative to Allergan’s BOTOX.

The US Food and Drug Administration (FDA) has issued a complete response letter (CRL) to Evolus, rejecting its biologics license application (BLA) for DWP-450 (prabotulinumtoxinA) for chemistry, manufacturing, and controls (CMC) deficiencies.

The candidate – an alternative to Allergan’s onabotulinumtoxinA (BOTOX) – is designed to temporarily improve the appearance of moderate to severe ‘frown lines’, also known as glabellar lines.

“We believe the CMC questions are very reasonable, since over half of the questions have already been completed and most were already in progress, which is why we believe we can respond to the FDA very quickly within the 90-day time frame,” ​a spokesperson told us.

“We now have the line of sight necessary to build our commercial infrastructure.

“We look forward to working closely with the FDA and remain committed to bringing DWP-450 to market by spring 2019,” ​the spokesperson added.

US FDA validates troubled CMO site

Evolus was however pleased to announce its contract manufacturing organisation’s (CMO’s) troubled facility had received FDA approval.

Last year, ten manufacturing violations​ landed Daewoong Pharmaceutical a Form 483​ for its Gyeonggi-do-based site in South Korea – a facility purposely built to make DWP-450.

According to Evolus, the FDA has since issued an establishment inspection report (EIR) to Daewoong confirming the favourable completion of a pre-approval inspection.

Evolus says the Daewoong facility will support commercial production following the anticipated approval of its lead candidate.

“We appreciate our continued relationship with Daewoong and the work of our entire team as we continue to advance our BLA submission towards expected approval,” ​the Evolus spokesperson told us.

Related news

Show more

Related products

show more

dPCR Case Study

dPCR Case Study

CellCarta | 08-Aug-2022 | Case Study

Streamline your adoptive cell therapy program with digital PCR. Our team has a unique expertise in digital and quantitative PCR to support you in ensuring...

The Reagents Behind Much of Molecular Biology

The Reagents Behind Much of Molecular Biology

Thermo Fisher Scientific | 25-Jul-2022 | Case Study

The ability to amplify, modify and fabricate DNA is fundamental to modern molecular biology. Why do so many researchers take their constituent parts for...

Microsampling in Early Phase Drug Development

Microsampling in Early Phase Drug Development

Altasciences | 10-May-2022 | Technical / White Paper

Microsampling significantly lessens the volume of blood and plasma/serum that is collected and analyzed to determine circulating concentrations of therapeutic...

Consideration and Options for Prefilled Syringes

Consideration and Options for Prefilled Syringes

Baxter BioPharma Solutions | 16-Feb-2022 | Technical / White Paper

Convenience, product differentiation, and less waste are great reasons for developing a product in a prefilled syringe. Baxter’s whitepaper describes the...

Related suppliers